Enterprise AI may be the quieter side of the AI boom, but it's where some of the most significant opportunities are emerging. Palantir is positioning itself at the center of that transformation.

Replimune received an FDA denial for accelerated approval of RP1+Opdivo in melanoma, with trial concerns outweighing strong data. Read why REPL stock is a hold.

Using the Detect and Avoid System, the MQ-9B operated in U.S. airspace like any other piloted aircraft, without the need for the special handling usually ...

Water treatment workers are grappling with how to protect against a new threat: hackers burrowing into the system and ...